GPT and chronic kidney disease: Biochemical analysis of the serum showed that no differences were found for ALT and AST enzymatic activity (two markers of liver toxicity), in all CKD groups versus control rats, demonstrating that treatment with PPi and the combination of SBI-425 + PPi inhibited CKD-induced arterial media calcification without affecting liver function.